Wilson M, Wasserman M, Breton MC, McDade C, Earnshaw S, Farkouh R. Potential clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Canada. Poster presented at the 2016 Canadian Immunization Conference; December 6, 2016. Ottawa, Canada.
Mauskopf J, Earnshaw S. A methodological review of US budget-impact models for new drugs. Pharmacoeconomics. 2016 Nov;34(11):1111-31. doi: 10.1007/s40273-016-0426-8
Mauskopf J, Earnshaw SR, Mullins CD, Brogan A. Building a budget impact model: budget impact analysis training. Presented at the 2016 ISPOR Training Courses; November 2016. Durham, NC.
Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2016 ISPOR 19th Annual European Congress; October 30, 2016. Vienna, Austria. Previously presented at the ISPOR 20th Annual International Meeting.
Earnshaw SR, Mullins CD, Brogan AJ. Budget impact analysis I: a 6-step approach. Presented at the 2016 ISPOR 19th Annual European Congress; October 30, 2016. Vienna, Austria. Previously presented at the ISPOR 18th Annual European Congress.
Wilson M, Lim J, Gandhi P, Wang C, Sander S, McDade C, Earnshaw S. Economic analysis of oral anticoagulants in the prevention of vascular events in Medicare patients with nonvalvular atrial fibrillation. Poster presented at the 38th Annual North American Meeting of the Society for Medical Decision Making; October 25, 2016. Vancouver, Canada.
Demarteau N, Standaert B, Earnshaw S. Mathematical programming modeling to optimise allocation of healthcare interventions. In: Ethgen O, Staginnus U, editors. The future of health economics. New York: NY. Routledge; 2016.
Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Claudie C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res. 2016 Jun;8:275-85.
Mauskopf JA, Mullins CD, Earnshaw SR. Budget impact analysis I: a 6-step approach. Presented at the 2016 ISPOR 21st Annual International Meeting; May 22, 2016. Washington, DC. Previously presented at the ISPOR 18th Annual European Congress.
Earnshaw SR, Brogan A, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2016 ISPOR 21st Annual International Meeting; May 22, 2016. Washington, DC. Previously presented at the ISPOR 20th Annual International Meeting.
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Graham J, Xuan D, Luthra R, Borker R, Earnshaw SE, Lim J. Budget impact analysis of afatinib for the first-line treatment of metastatic non-small cell lung cancer patients with epidermal growth factor receptor exon 19 deletion mutations in a U.S. health plan. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S30.
Wilson MR, Gutierrez B, Offord S, Blanchette CM, Eramo A, Earnshaw SR, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006 Nov 28;37(11):2751-8.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage. Poster presented at the 2006 International Stroke Conference; February 17, 2006. [abstract] Stroke. 2006 Nov; 37(11):2751.
Earnshaw SR, Wilson MR, Joshi AV. Budgetary impact analysis of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US health plan perspective. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A329.
Earnshaw SR, Graham CN, Amonkar MM, Poston SA, Barr CE. Cost-effectiveness of ibandronate intravenous injection in the treatment of US women with postmenopausal osteoporosis. Poster presented at the 2006 American College of Rheumatology Scientific Meeting; November 2006.
Earnshaw SR, Pignone M, Tice J, Pletcher M. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Poster presented at the Annual Meeting of the Institute for Operations Research and the Management Sciences; November 2006.
Cowell W, Amonkar M, Cooper A, Earnshaw SR, Beard SM, Lynch N, Middelhoven H. Ibandronate vs. alendrolate: a cost-effectiveness analysis using persist results. Poster presented at the 2006 American College of Rheumatology Scientific Meeting; November 2006.
Shearer A, Gazzard B, Graham CN, Davis EA, Mauskopf J, Kitahata M, Saag MS, Earnshaw SR. Simulation modeling of adherence and resistance on long-term outcomes in HIV. Poster presented at the Infectious Disease Society of America 44th Annual Meeting; October 15, 2006.
Graham CN, Earnshaw SR, Smith DG, Hogue S, Gitchell J, Marsh H, Becker W, Saunders M. Assessing the impact of smoking cessation therapies on a managed care organization's budget. Poster presented at the Academy of Managed Care Pharmacy Educational Conference; October 7, 2006.
Earnshaw SR, Beard SM, Lynch NO, Cooper A, Cowell W, Middelhoven H. A comparison of the cost-effectiveness of bisphosphonates using persistence data from a UK propsective rct. Poster presented at the 28th Annual Meeting of the American Society for Bone and Mineral Research; September 19, 2006.
Schnitzler MA, Earnshaw SR, Graham CN, Irish WD, Sato R. Lifetime cost-effectiveness of calcineruin inhibitor-free immunosuppressive treatment after de novo renal transplantation. Poster presented at the World Transplant Congress; July 27, 2006.
Earnshaw SR, Beard SM, Lynch NO, Cowell W. Ibandronate in the treatment of postmenopausal osteoporosis: a cost-effectiveness analysis in the UK. Poster presented at the European League Against Rheumatism Annual European Congress of Rheumatology; June 24, 2006.
Zlateva GP, Javitt JC, Earnshaw SR, Pliel AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2006 EURETINA Congress; May 21, 2006. Lisbon, Portugal. Previously presented at the 2005 ISPOR 8th Annual European Congress.
Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson K. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA.
Earnshaw SR, Moride Y, Moshyk A, Rochon S. Cost-effectiveness of macugen compared to photodynamic therapy (PDT) with verteporfin and standard care in the treatment of subfoveal wet age-related macular degeneration (AMD) in the elderly in Canada. Poster presented at the Third Annual Canadian Joint Therapeutics Congress, Canadian Association for Population Therapeutics; May 13, 2006. Toronto, Canada.
Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson KP. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Value Health. 2006 May 1;9(3):A81-2.
Earnshaw SR, Graham CN, Amonkar MM, Barr C. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A163.
Earnshaw SR, Wilson MR, Joshi AV. Short-term cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Value Health. 2006 May 1;9(3):A8.
Earnshaw SR, Graham CN, Amonkar MM, Barr CE. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Value Health. 2006 May 1;9(3):A163.
Earnshaw SR, Joshi AV, Wilson MR. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US managed care perspective. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 7, 2006.
Earnshaw SR, Gricar J. Good practices for high quality decision analytic models. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 6, 2006.
Javitt JC, Earnshaw SR, Graham CN, Brogan AJ, Zlateva GP, Pleil AM. Cost-effectiveness of Macugen versus no treatment in age-related macular degeneration patients. Poster presented at the Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting; April 2006.
Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006 Mar 7;144(5):326-36.
Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ. Cost-effectiveness model for age-related macular degeneration: comparing Macugen® to Visudyne®. Poster presented at the 2006 World Ophthalmology Congress; February 2006. Previously presented at the ISPOR 8th Annual European Congress.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.